Parexel, Partex Agree to Drug Discovery and Development Partnership
Collaboration to pair artificial intelligence proficiencies with clinical research expertise.
Parexel, a contract research organization (CRO), and Partex, a data-to-drugs pharma platform, have inked a deal aiming to leverage artificial intelligence (AI)-powered solutions to accelerate drug discovery and development for biopharmaceutical customers worldwide and de-risk the assets in their portfolios. Under the partnership, Partex’s clinical trial execution will be ran by Parexel as the preferred CRO provider. The organizations will also work together to improve customer clinical trial execution through the Partex-validated AI platform.
"One of the biggest and most complex challenges in drug development is anticipating the investigational therapies that will be safe and effective treatment options,” said Jamie Macdonald, CEO, Parexel, in a company press release. “Our innovative alliance with Partex helps to address this challenge by bringing to the forefront those assets with the strongest probability of clinical success, in turn enabling customers to focus their time and resources where it is most beneficial to patients.”
Reference: Parexel and Partex Announce Innovative Alliance Leveraging Artificial Intelligence and Big Data to Accelerate Drug Discovery and Development. Parexel. August 15, 2023. Accessed September 5, 2023. https://newsroom.parexel.com/news-releases/news-release-details/parexel-and-partex-announce-innovative-alliance-leveraging?utm_campaign=PostBeyond&utm_source=LinkedIn&utm_medium=449887&utm_term=Parexel+and+Partex+Announce+Innovative+Alliance+Leveraging+Artificial+Intelligence+and+Big+Data+to+Accelerate+Drug+Discovery+and+Development+%7C+Parexel+International+Corporation
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
